Antenatal glucocorticoids supplementation and central nervous system development

Maternal antenatal therapy with glucocorticoids (GC) is routinely used to prevent lung immaturity. The potential harmful effects on other organs, including in particular the central nervous system (CNS), are still controversial. In the present review we aimed to investigate: i) the beneficial and de...

Full description

Saved in:
Bibliographic Details
Published inCurrent drug metabolism Vol. 14; no. 2; p. 160
Main Authors Gazzolo, Diego, Serpero, Laura D, Frigiola, Alessandro, Abella, Raul, Dro Giamberti, Alessan, Li Volti, Giovanni, Michetti, Fabrizio
Format Journal Article
LanguageEnglish
Published Netherlands 01.02.2013
Subjects
Animals
Central Nervous System - drug effects
Central Nervous System - embryology
Female
Glucocorticoids - pharmacology
Glucocorticoids - therapeutic use
Humans
Infant, Newborn
Maternal-Fetal Exchange
Pregnancy
Receptors, Glucocorticoid - metabolism
Respiratory Distress Syndrome, Newborn - prevention & control
Online AccessGet more information

Cover

More Information
Summary:Maternal antenatal therapy with glucocorticoids (GC) is routinely used to prevent lung immaturity. The potential harmful effects on other organs, including in particular the central nervous system (CNS), are still controversial. In the present review we aimed to investigate: i) the beneficial and detrimental effects of antenatal GC treatment in both human and animal models; ii) the potential usefulness of biochemical markers such as calcium binding proteins (S100B, synaptophysin) and cytoskeletal protein of neurons and dendrites (MAP2) in the perinatal period, and iii) whether the assessment of brain markers in different biological fluids could constitute a promising tool for the monitoring of CNS function and/or developmental in fetuses and newborns whose mothers assumed GC antenatally.
ISSN:1875-5453
DOI:10.2174/138920013804870682